The Ensign Group Earnings Call Transcripts
Fiscal Year 2026
-
Record occupancy and strong skilled mix drove double-digit revenue and earnings growth in Q1 2026, prompting raised annual guidance. Strategic acquisitions, robust liquidity, and continued clinical excellence position the company for sustained expansion.
-
Consistent growth in occupancy and earnings is supported by a strong leadership pipeline and successful integration of acquisitions. Guidance for 2026 projects double-digit revenue and EPS growth, with further upside from demographic trends and operational improvements. Regulatory and reimbursement risks are actively managed, and the real estate strategy adds value.
Fiscal Year 2025
-
Record financial and operational results were achieved, with strong revenue and EPS growth, robust acquisition activity, and all-time high occupancy rates. FY26 guidance projects continued double-digit growth, supported by a healthy M&A pipeline and disciplined capital allocation.
-
Record quarterly results driven by strong clinical outcomes, occupancy, and skilled mix growth. Raised 2025 guidance for both EPS and revenue, reflecting robust organic and acquisition-driven expansion, with disciplined capital allocation and strong liquidity.
-
Record Q2 with 18%+ growth in revenue and EPS, raised 2025 guidance, and strong acquisition pace. Low leverage, robust liquidity, and disciplined portfolio integration support continued expansion.
-
Sustained growth is driven by acquisitions, organic improvements, and demographic tailwinds, with a focus on expanding specialized care and entering new markets through a leader-driven, methodical approach. Real estate strategy balances ownership, operation, and partnerships to support industry growth.
-
Record-setting quarter with double-digit growth in revenue, net income, and EPS, driven by strong occupancy, skilled mix, and strategic acquisitions. Raised 2025 guidance for both earnings and revenue, supported by robust liquidity and disciplined capital deployment.
Fiscal Year 2024
-
Record financial and clinical results in 2024 were driven by strong organic growth and disciplined acquisitions, with significant expansion into new markets and a robust outlook for 2025. Liquidity and balance sheet strength support continued growth, while risk from reimbursement changes and acquisition delays is being managed.
-
Leadership development and disciplined acquisitions are driving growth, with a strong focus on operational efficiency and compliance. Regulatory changes are expected to be favorable, and Medicaid funding remains stable, while the organization maintains a mission-driven, locally empowered model.
-
Record quarterly results driven by strong organic and acquisition growth, with same-store occupancy and skilled mix at new highs. Raised 2024 earnings and revenue guidance, maintained low leverage, and highlighted robust acquisition pipeline and disciplined expansion.
-
Record quarterly results driven by strong occupancy, skilled mix growth, and disciplined acquisitions. Raised 2024 guidance for both earnings and revenue, with robust liquidity and continued deleveraging. Demand remains strong, with improving labor trends and regulatory confidence.